Illinois 100th Regular Session Status: Passed Senate

SB 702 — CONTROLLED SUB-U-47700

Last action — Session Sine Die

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 100th Regular Session. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Amends the Illinois Controlled Substances Act. Adds 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (some trade or other name: U-47700) as a Schedule I controlled substance. Effective immediately.

Bill Text

What changed in the latest version

22 added · 40 removed

Plain-language change summary

The recent amendment to Bill SB 702 adds specific language to classify a substance known as U-47700 as a Schedule I controlled substance in Illinois. This classification indicates that U-47700 has a high potential for abuse and no accepted medical use, making it illegal in the state. This change is important as it aims to strengthen drug regulation and public safety by restricting the availability of this substance, which has been associated with health risks.

→
Previous
Latest
*LRB10007354RLC17417b* SB0702 100TH GENERAL ASSEMBLY State of Illinois and 2018 SB0702 Introduced 1/30/2017, by Sen.
SB0702 Engrossed LRB100 07354 RLC 17417 b AN ACT concerning criminal law.
Kyle McCarter SYNOPSIS AS INTRODUCED:
ILCS 570/204 from Ch.
56 1/2, par.
1204 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamid(some trade or other name:
U-47700) as a Schedule I controlled substance.
Effective immediately.
LRB100 07354 RLC 17417 b CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY A BILL FOR SB0702 LRB100 07354 RLC 17417 b AN ACT concerning criminal law.
SB0702 - 2 - LRB100 07354 RLC 17417 b (5) Alphamethadol;
SB0702 Engrossed - 2 - LRB100 07354 RLC 17417 b (5) Alphamethadol;
SB0702 - 3 - LRB100 07354 RLC 17417 b (20) Dimethylthiambutene;
SB0702 Engrossed - 3 - LRB100 07354 RLC 17417 b (20) Dimethylthiambutene;
SB0702 - 4 - LRB100 07354 RLC 17417 b (38) Phenampromide;
SB0702 Engrossed - 4 - LRB100 07354 RLC 17417 b (38) Phenampromide;
SB0702 - 5 - LRB100 07354 RLC 17417 b (6) Cyprenorphine;
SB0702 Engrossed - 5 - LRB100 07354 RLC 17417 b (6) Cyprenorphine;
(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this SB0702 - 6 - LRB100 07354 RLC 17417 b paragraph only, the term "isomer" includes the optical, position and geometric isomers):
(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this SB0702 Engrossed - 6 - LRB100 07354 RLC 17417 b paragraph only, the term "isomer" includes the optical, position and geometric isomers):
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy- 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b] SB0702 - 7 - LRB100 07354 RLC 17417 b indole;
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy- 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b] SB0702 Engrossed - 7 - LRB100 07354 RLC 17417 b indole;
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- SB0702 - 8 - LRB100 07354 RLC 17417 b dibenzo (b,d) pyran;
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- SB0702 Engrossed - 8 - LRB100 07354 RLC 17417 b dibenzo (b,d) pyran;
SB0702 - 9 - LRB100 07354 RLC 17417 b (26) 2,5-dimethoxy-4-ethylamphetamine (another name:
SB0702 Engrossed - 9 - LRB100 07354 RLC 17417 b (26) 2,5-dimethoxy-4-ethylamphetamine (another name:
SB0702 - 10 - LRB100 07354 RLC 17417 b and homologues where side chain n=4, 6, or 7;
SB0702 Engrossed - 10 - LRB100 07354 RLC 17417 b and homologues where side chain n=4, 6, or 7;
SB0702 - 11 - LRB100 07354 RLC 17417 b (41) 1-(2-cyclohexylethyl)-3- (2-methoxyphenylacetyl)indole Some trade or other names:
SB0702 Engrossed - 11 - LRB100 07354 RLC 17417 b (41) 1-(2-cyclohexylethyl)-3- (2-methoxyphenylacetyl)indole Some trade or other names:
SB0702 - 12 - LRB100 07354 RLC 17417 b (44) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl- 2-piperidinyl)methyl, or 2-(4- morpholinyl)ethyl whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent.
SB0702 Engrossed - 12 - LRB100 07354 RLC 17417 b (44) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl- 2-piperidinyl)methyl, or 2-(4- morpholinyl)ethyl whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent.
(46) Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, SB0702 - 13 - LRB100 07354 RLC 17417 b aryl halide, alkyl aryl halide, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not substituted in the cyclohexyl ring to any extent.
(46) Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, SB0702 Engrossed - 13 - LRB100 07354 RLC 17417 b aryl halide, alkyl aryl halide, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not substituted in the cyclohexyl ring to any extent.
SB0702 - 14 - LRB100 07354 RLC 17417 b (51) 4-Fluoromethcathinone;
SB0702 Engrossed - 14 - LRB100 07354 RLC 17417 b (51) 4-Fluoromethcathinone;
including, but not limited to, XLR11, SB0702 - 15 - LRB100 07354 RLC 17417 b UR144, FUB-144;
including, but not limited to, XLR11, SB0702 Engrossed - 15 - LRB100 07354 RLC 17417 b UR144, FUB-144;
(62) N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, SB0702 - 16 - LRB100 07354 RLC 17417 b 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent:
(62) N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, SB0702 Engrossed - 16 - LRB100 07354 RLC 17417 b 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent:
including, but not limited to, SB0702 - 17 - LRB100 07354 RLC 17417 b THJ-018, THJ-2201;
including, but not limited to, SB0702 Engrossed - 17 - LRB100 07354 RLC 17417 b THJ-018, THJ-2201;
(67) N-(1-amino-3,3-dimethyl-1-oxobutan- 2-yl)-1H-indazole-3-carboxamide with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any SB0702 - 18 - LRB100 07354 RLC 17417 b extent:
(67) N-(1-amino-3,3-dimethyl-1-oxobutan- 2-yl)-1H-indazole-3-carboxamide with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any SB0702 Engrossed - 18 - LRB100 07354 RLC 17417 b extent:
(70) Methyl 2-(1H-indazole-3-carboxamido)- 3-methylbutanoate with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole SB0702 - 19 - LRB100 07354 RLC 17417 b ring to any extent:
(70) Methyl 2-(1H-indazole-3-carboxamido)- 3-methylbutanoate with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2- piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole SB0702 Engrossed - 19 - LRB100 07354 RLC 17417 b ring to any extent:
SB0702 - 20 - LRB100 07354 RLC 17417 b (4) Methcathinone (some other names:
SB0702 Engrossed - 20 - LRB100 07354 RLC 17417 b (4) Methcathinone (some other names:
Unless specifically excepted, any chemical compound not including bupropion, structurally SB0702 - 21 - LRB100 07354 RLC 17417 b derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or more of the following ways:
Unless specifically excepted, any chemical compound not including bupropion, structurally SB0702 Engrossed - 21 - LRB100 07354 RLC 17417 b derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or more of the following ways:
This Act takes effect upon SB0702 - 22 - LRB100 07354 RLC 17417 b becoming law.
This Act takes effect upon SB0702 Engrossed - 22 - LRB100 07354 RLC 17417 b becoming law.
⬇ Download PDF
View plain text versions (2)

Action History

  1. Session Sine Die

  2. Rule 19(a) / Re-referred to Rules Committee

  3. Final Action Deadline Extended-9(b) July 7, 2017

  4. Final Action Deadline Extended-9(b) June 30, 2017

  5. Placed on Calendar Order of 3rd Reading - Short Debate

  6. Final Action Deadline Extended-9(b) May 31, 2017

  7. Held on Calendar Order of Second Reading - Short Debate

  8. Second Reading - Short Debate

  9. Placed on Calendar 2nd Reading - Short Debate

  10. Do Pass / Short Debate Judiciary - Criminal Committee; 013-000-000

  11. Committee Deadline Extended-Rule 9(b) May 26, 2017

  12. Assigned to Judiciary - Criminal Committee

  13. Referred to Rules Committee

  14. First Reading

  15. Chief House Sponsor Rep. Deb Conroy

  16. Arrived in House

  17. Third Reading - Passed; 056-000-000

  18. Added as Chief Co-Sponsor Sen. Dan McConchie

  19. Added as Chief Co-Sponsor Sen. Melinda Bush

  20. Placed on Calendar Order of 3rd Reading March 15, 2017

  21. Second Reading

  22. Added as Chief Co-Sponsor Sen. Michael Connelly

  23. Placed on Calendar Order of 2nd Reading March 2, 2017

  24. Do Pass Criminal Law; 011-000-000

  25. Assigned to Criminal Law

  26. Referred to Assignments

  27. First Reading

  28. Filed with Secretary by Sen. Kyle McCarter

Sponsors

  • Kyle McCarter · Cosponsor

Sponsorship breakdown

Export CSV (upgrade) →

0 sponsors · 1 co-sponsors · 182 not signed on

Sponsors (0)

None.

Co-sponsors (1)

  • Kyle McCarter

Not signed on (182)

182 members have not signed on to this bill.

Show all 182 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Third Reading

Passed 56 Yea · 0 Nay · 3 Other
Party YeaNayPresentNot Voting
Unaffiliated 34003
Republican 8000
Democrat 14000
Total 56003
% of votes cast 95%0%0%5%
How each member voted (59)
Member Party Vote
Bertino-Tarrant — Yea
Biss — Yea
Bivins — Yea
Bush — Yea
Clayborne — Yea
Connelly — Yea
McConnaughay — Yea
McCann — Yea
McCarter — Yea
Mulroe — Yea
Rooney — Yea
Muñoz — Yea
Silverstein — Yea
Bennett — Yea
McGuire — Yea
Steans — Yea
Trotter — Yea
Brady — Yea
Hutchinson — Yea
Cullerton — Yea
Link — Yea
Cullerton, T. — Yea
Oberweis — Yea
Harris — Not Voting
Haine — Not Voting
Radogno — Yea
Nybo — Yea
Raoul — Yea
Righter — Yea
Sandoval — Yea
Schimpf — Yea
Landek — Yea
Manar — Yea
Althoff — Yea
Martinez — Not Voting
Barickman — Yea
Van Pelt — Yea
Bill Cunningham Democrat Yea
Cristina Castro Democrat Yea
David Koehler Democrat Yea
Don Harmon Democrat Yea
Emil Jones, III Democrat Yea
Julie A. Morrison Democrat Yea
Kimberly A. Lightford Democrat Yea
Lakesia Collins Democrat Yea
Laura M. Murphy Democrat Yea
Linda Holmes Democrat Yea
Mattie Hunter Democrat Yea
Michael E. Hastings Democrat Yea
Omar Aquino Democrat Yea
Steve Stadelman Democrat Yea
Chapin Rose Republican Yea
Dale Fowler Republican Yea
Dan McConchie Republican Yea
Dave Syverson Republican Yea
Jil Tracy Republican Yea
Neil Anderson Republican Yea
Sue Rezin Republican Yea
Travis Weaver Republican Yea

Official roll call →

Subjects

public-safety
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 702 do?
Amends the Illinois Controlled Substances Act. Adds 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (some trade or other name: U-47700) as a Schedule I controlled substance. Effective immediately.
Who sponsors SB 702?
SB 702 is sponsored by Kyle McCarter.
What is the current status of SB 702?
This bill died with 100th Regular Session. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track SB 702?
Track SB 702 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 702

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 702

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →